AUTH/3658/6/22 - Complainant v Novartis

Allegations about an email regarding a promotional symposium for Mayzent(siponimod)

  • Received
    13 June 2022
  • Case number
  • Applicable Code year
  • Completed
    19 June 2023
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to an email distributed by a multiple sclerosis independent education provider about a Novartis promotional symposium.

The Panel ruled no breach of the following Clauses of the 2021 Code as:

• the email had been certified
• the complainant had not established that reference to ‘Mayzent for SPMS with Active Disease’, within the particular material at issue, promoted Mayzent in a manner that was inconsistent with its SPC or was unqualified as alleged
• the complainant had not established that the material had not made clear that the webinar was only for health professionals.

No Breach of Clause 2

Requirement that activities or material must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards

No Breach of Clause 8.1

Requirement to certify promotional material

No Breach of Clause 11.2

Requirement not to promote a medicine in a manner that was inconsistent with its SPC

This summary is not intended to be read in isolation.
For full details, please see the full case report below.